Last updated on January 2020

Safety Tolerability and Efficacy of IONIS-GHR-LRx in Patients With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands


Brief description of study

The purpose is to assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in up to 60 Patients with Acromegaly

Detailed Study Description

This short-term study will assess changes in serum insulin-like growth factor 1 (IGF-1) over a 16-week treatment period in a patient population diagnosed with Acromegaly being treated with Long-acting Somatostatin Receptor Ligands (SRL)

Clinical Study Identifier: NCT03548415

Find a site near you

Start Over

Cedars-Sinai Medical Center

Los Angeles, CA United States
  Connect »

Northwestern University

Chicago, IL United States
  Connect »

Palm Research Center, Inc.

Las Vegas, NV United States
  Connect »

Cleveland Clinic

Cleveland, OH United States
  Connect »

Rostov State Medical University

Rostov-On-Don, Russian Federation
  Connect »

Almazov National Medical Research Centre

St. Petersburg, Russian Federation
  Connect »